Intellia Therapeutics Inc
$ 12.35
1.23%
11 Jun - close price
- Market Cap 1,798,226,000 USD
- Current Price $ 12.35
- High / Low $ 12.45 / 11.81
- Stock P/E N/A
- Book Value 5.16
- EPS -3.52
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.56 %
- 52 Week High 28.25
- 52 Week Low 7.95
About
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$26.63
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-09 | 2023-08-03 |
| Reported EPS | -0.81 | -0.83 | -0.92 | -0.98 | -1.1 | -1.27 | -1.34 | -1.52 | -1.12 | -1.46 | -1.38 | -1.4 |
| Estimated EPS | -0.9 | -0.96 | -1 | -1.01 | -1.27 | -1.3164 | -1.37 | -1.2 | -1.36 | -1.44 | -1.5 | -1.33 |
| Surprise | 0.09 | 0.13 | 0.08 | 0.03 | 0.17 | 0.0464 | 0.03 | -0.32 | 0.24 | -0.02 | 0.12 | -0.07 |
| Surprise Percentage | 10% | 13.5417% | 8% | 2.9703% | 13.3858% | 3.5248% | 2.1898% | -26.6667% | 17.6471% | -1.3889% | 8% | -5.2632% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.8 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTLA
2026-06-11 11:12:19
This article identifies and discusses high-growth tech stocks in the US market, noting the market's recent decline but overall annual growth. It highlights key companies like LightPath Technologies, Intellia Therapeutics, and AppLovin, detailing their financial performance, growth potential, and strategic investments. The report emphasizes the importance of innovation, scalability, and strong fundamentals for these companies to thrive amidst market fluctuations.
2026-06-11 07:39:32
Intellia Therapeutics (NTLA) director Muna Bhanji was granted 9,200 Restricted Stock Units (RSUs) and 13,300 stock options, as detailed in a recent Form 4 filing. The RSUs increase her direct common stock holdings to 36,403 shares, while the stock options have an exercise price of $12.89 and vest within one year or by the next annual stockholder meeting. This transaction represents an equity compensation award rather than a stock purchase.
2026-06-11 04:10:05
This article is a Form 4 statement from Intellia Therapeutics, detailing changes in beneficial ownership of securities for Director Brian Goff, as required by the SEC.
2026-06-10 23:10:05
Intellia Therapeutics director William J. Chase received new equity awards on June 9, 2026, comprising 9,200 restricted stock units and stock options for 13,300 shares at an exercise price of $12.89. The stock options vest fully on the earlier of one year from the grant date or the next annual stockholders’ meeting and expire on June 8, 2036. Following this grant, Chase directly holds 143,893 common shares of Intellia.
2026-06-10 23:10:05
Intellia Therapeutics director Fred E. Cohen was granted 9,200 restricted stock units and a stock option for 13,300 shares, according to a recent SEC Form 4 filing. The RSUs increase his direct common stock holdings to 216,653 shares, while the stock option has an exercise price of $12.89 per share and vests fully on the earlier of one year from the June 9, 2026 grant date or the next annual stockholders' meeting, expiring on June 8, 2036. These transactions are compensation-related grants, not open-market trades.
2026-06-10 23:10:05
Intellia Therapeutics director Frank Verwiel was granted 9,200 restricted stock units (RSUs) and a stock option for 13,300 shares, reflecting new equity awards rather than open-market transactions. Following these grants, Verwiel directly holds 35,148 common shares and the new stock option with an exercise price of $12.89 per share. The option vests on the earlier of one year from the June 9, 2026 grant date or the next annual stockholder meeting and expires on June 8, 2036.
